The Long Run• Apr 7, 2026• 1:16:43Interview

Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery

From The Long Run

Abbas Kazimi•CEO, Nimbus Therapeutics

Executive Summary

Nimbus Therapeutics has pioneered a capital-efficient biotech model, using a lean team, virtual R&D, and a unique LLC/C-corp structure to develop and monetize high-value assets.
The company's strategy was validated by the $4 billion upfront sale of its TYK2 inhibitor, zazocytinib, to Takeda, which is now poised to become a multi-billion dollar blockbuster for autoimmune diseases.
Nimbus employs a rigorous portfolio strategy, terminating 75% of its programs to recycle capital into the most promising assets, such as its current WRN (cancer) and SIK2 (immune disorders) inhibitors.
The company's drug discovery approach is rooted in computational chemistry and structure-based design, viewing technology and AI not as an 'answer engine' but as a 'thinking amplifier' to augment human expertise.

12 quotes

Concerns Raised

Inherent risk of drug development failure, despite past successes.
Maintaining a lean, agile culture as the company continues its successful 'rinse and repeat' model.
Dependence on large pharma partners for late-stage development and commercial success of its assets.

Opportunities Identified

Blockbuster potential of the Takeda-partnered TYK2 inhibitor (zazocytinib) in psoriasis and other autoimmune diseases.
Advancement of the internal pipeline, including a WRN inhibitor for cancer and a SIK2 inhibitor for immune disorders.
Collaboration with Eli Lilly to develop small molecule drugs for high-value metabolic disorders, including obesity.

Key Themes

Capital-Efficient Biotech Model

Nimbus operates with a lean team of 70-80 people and a virtual R&D model, avoiding the overhead of internal labs. This is combined with a unique LLC holding company and C-corp subsidiary structure, allowing for the sale of individual assets (like the Takeda and Gilead deals) while keeping the core discovery team intact to 'rinse and repeat'.

This model offers an alternative to the traditional 'all-or-nothing' biotech path of either going public or being fully acquired, providing a repeatable framework for generating significant investor returns from a core platform.

Strategic Asset Monetization

The company has a track record of successfully monetizing its drug programs through high-value deals with major pharmaceutical companies. Key examples include the $1.2 billion sale of its ACC inhibitor program to Gilead and the landmark $4 billion upfront sale of its TYK2 inhibitor to Takeda.

This demonstrates the ability to create best-in-class assets that command premium valuations, validating both the scientific platform and the business strategy of partnering for late-stage development and commercialization.

Computationally-Driven Drug Discovery

Nimbus's scientific approach is centered on using computational chemistry and structural biology to design small molecules with intent, rather than relying on high-throughput screening. This allows them to tackle difficult targets and engineer molecules with high potency and selectivity, as evidenced by the 1.5 million-fold selectivity of their TYK2 inhibitor.

This highlights the power of modern computational tools to turn complex biology into more tractable engineering problems, potentially increasing the speed and success rate of drug discovery.

Disciplined Portfolio Management

A core tenet of Nimbus's strategy is a high portfolio attrition rate, intentionally terminating about 75% of its programs. This disciplined approach has allowed the company to recycle over $100 million back into its most promising early-stage discovery efforts, focusing resources where they can have the most impact.

This aggressive 'fail fast' philosophy is crucial for capital efficiency in the high-risk biotech industry, ensuring that investment is concentrated on assets with the highest probability of clinical and commercial success.

Get started free

Topics

Nimbus Therapeutics Biotech Business Models Capital Efficiency Asset Monetization Drug Discovery Small Molecule Drugs Computational Chemistry Structure-Based Design TYK2 Inhibitors Zazocytinib Takeda Pharmaceuticals Gilead Sciences Eli Lilly Psoriasis Autoimmune Diseases WRN Inhibitors SIK2 Inhibitors Portfolio Management Virtual Biotech

Processed May 4, 2026 yt-dlp + mlx-whisper + Gemini

You're reading a preview

Get started free →